Literature DB >> 1369172

Regulatory considerations when developing biological products. Report of the Center for Biologics Evaluation and Research.

R W Kozak1, C N Durfor, C L Scribner.   

Abstract

The Center for Biologics Evaluation and Research, whose regulatory authority includes monoclonal antibodies, cytokines, vaccines, toxins and somatic cellular therapies, communicates to sponsors issues for consideration in the development of biological products through the publication of "Points to Consider" and "Guideline" documents. This paper summarizes the available "Points to Consider" and "Guideline" documents and outlines recommendations from these documents for characterizing the cells used to produce biological products.

Mesh:

Substances:

Year:  1992        PMID: 1369172     DOI: 10.1007/bf02521747

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  2 in total

1.  An FDA perspective of manufacturing changes for products in human use.

Authors:  C N Durfor; C L Scribner
Journal:  Ann N Y Acad Sci       Date:  1992-10-13       Impact factor: 5.691

2.  A Mus dunni cell line that lacks sequences closely related to endogenous murine leukemia viruses and can be infected by ectropic, amphotropic, xenotropic, and mink cell focus-forming viruses.

Authors:  M R Lander; S K Chattopadhyay
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

  2 in total
  1 in total

1.  Cultivation and Differentiation of Encapsulated hMSC-TERT in a Disposable Small-Scale Syringe-Like Fixed Bed Reactor.

Authors:  Christian Weber; Sebastian Pohl; Ralf Pörtner; Christine Wallrapp; Moustapha Kassem; Peter Geigle; Peter Czermak
Journal:  Open Biomed Eng J       Date:  2007-10-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.